SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, today announced exclusive, worldwide licenses to the antiviral resistance microarray-based influenza detection technology (AVR-Chip) and to the microarray-based influenza B detection technology (BChip), both developed by scientists at the University of Colorado at Boulder (CU-Boulder) in close collaboration with the U.S. Centers for Disease Control and Prevention (CDC).
